Basilea Looks To Progress Cancer Pipeline As It Expands Zevtera Use

Ceftobiprole Approved In China

Switzerland’s Basilea Pharmaceutica is progressing its lead oncology candidates and a second late-stage US clinical trial of ceftobiprole in difficult-to-treat infections.    

Meticillin Resistant Staphylococcus aureus
Meticillin-Resistant S aureus (MRAS) • Source: Shutterstock

Key priorities for Switzerland’s Basilea Pharmaceutica Ltd. this year include pursuing the US Phase III study of the fifth-generation cephalosporin ceftobiprole in serious infections, obtaining interim clinical trial results for its lead oncology candidates derazantinib and lisavanbulin, and helping partner CR Gosun launch ceftobiprole in China.

The Basel, Switzerland-based drug development company expects to complete enrolment into the Phase III ERADICATE study of the fifth-generation cephalosporin,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Anti-infective

More from Therapy Areas

Sanofi Doubles Down On Respiratory Vaccines With Vicebio Buy

 
• By 

The French major is paying $1.15bn For the UK biotech and its bivalent candidate, VXB-241.

Alkermes To Advance Alixorexton After Positive Phase II Narcolepsy Results

 

The biotech company is planning for Phase III based on positive topline results from Vibrance-1 in narcolepsy type 1 and remains optimistic about type 2 disease.

After Gilead Deal, Hookipa Hangs Up Its Hat

 
• By 

The Austrian firm is delisting from the NASDAQ and closing down.